Last reviewed · How we verify
ME-609
ME-609 is a hepatitis C virus (HCV) NS5B polymerase inhibitor that blocks viral RNA replication.
ME-609 is a hepatitis C virus (HCV) NS5B polymerase inhibitor that blocks viral RNA replication. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | ME-609 |
|---|---|
| Sponsor | Medivir |
| Drug class | HCV NS5B polymerase inhibitor |
| Target | HCV NS5B RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
ME-609 targets the NS5B RNA-dependent RNA polymerase, a non-structural protein essential for HCV genome replication. By inhibiting this enzyme, the drug prevents the virus from synthesizing new RNA copies, thereby suppressing viral replication and reducing viral load in infected patients.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Headache
- Fatigue
- Nausea
Key clinical trials
- Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis (PHASE3)
- Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents (PHASE3)
- Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients (PHASE3)
- Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |